ArticleVirology journal2026
Genomic characterization of SARS-CoV-2 variants circulating in the population of Bangui, Central African Republic (CAR) in 2022.
Article in Virology journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionWith the ongoing global resurgence of COVID-19, it is crucial to better understand past transmission dynamics to strengthen national preparedness for future surges. Since its emergence in Wuhan, China, in December 2019, SARS-CoV-2 has caused multiple waves of infection worldwide. The World Health Organization (WHO) has identified several variants of concern, including Alpha, Beta, Gamma, and Delta. At the end of 2021, the Omicron variant emerged in South Africa and rapidly spread across the globe. While many studies have explored the evolution and transmission of these variants, data from the Central African Republic remained limited. This study aimed to identify and characterize SARS-CoV-2 variants circulating in Bangui to support genomic surveillance and COVID-19 prevention strategies. Characterizing circulating variants provides essential information for the early detection of emerging lineages, the anticipation of potential epidemic waves, and the adaptation of public health strategies. METHODOLOGY: We conducted a retrospective, descriptive study in Bangui, Central African Republic (CAR), from January to August 2022. A total of 102 nasopharyngeal samples positive for SARS-CoV-2 (Ct ≤ 30), selected from the biobank of the Pasteur Institute in Bangui, were reanalyzed using multiplex qPCR to confirm their Ct values. Eligible samples were then sequenced using the MinION MK1C (Oxford Nanopore Technologies) platform, following the ARTIC Network protocol at the Institut Pasteur, Paris (CIBU). Bioinformatics processing using reads mapping to a reference genome, followed by consensus sequence generation, included standard steps of basecalling, demultiplexing, quality filtering, genome alignment, primer trimming, consensus generation, and variant calling. The different variants were described using the Nexstrain web application.
resultsThe results revealed that 66.7% of sequenced genomes (n = 68) had high coverage ≥ 80%, all belonging to the Omicron variant. Four sub-lineages were identified according to the Pangolin classification: BA.1 (14.7%), BA.2 (35.3%), BA.4.1 (4.4%), and BA.5.1 (45.6%). These sub-lineages were present in all eight districts, with a predominance in the eighth district, and were most frequently diagnosed in June (fourth wave of the epidemic).
conclusionOmicron was the only variant detected among successfully sequenced samples, although limited sampling and sequencing success restrict broader generalisation. It is crucial to establish continuous surveillance of SARS-CoV-2 to detect any emerging variants in real time, while strengthening sequencing capabilities at the national level. Continuous genomic surveillance is crucial to anticipate potential future COVID-19 waves and to enable timely public health responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.